EpiVax licenses novel immune-modulating technology to a global pharmaceutical company (undisclosed)
Posted on28 Apr 2017
TagsEpiVax, global pharma licensing deal, global pharmaceutical company, inlicensing in pharma, outlicensing in pharma
Comments0
EpiVax, a Providence-based biotechnology company, has licensed its novel immune-modulating technology to an undisclosed global pharmaceutical company, for use in autoimmune disease... Read More